𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficient four-drug cocktail therapy targeting amyloid-β peptide for Alzheimer's disease

✍ Scribed by Masashi Asai; Nobuhisa Iwata; Taisuke Tomita; Takeshi Iwatsubo; Shoichi Ishiura; Takaomi C. Saido; Kei Maruyama

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
669 KB
Volume
88
Category
Article
ISSN
0360-4012

No coin nor oath required. For personal study only.

✦ Synopsis

Cocktail treatment is an effective multidrug medication therapy for some diseases, such as cancer and AIDS, because of the additive or synergistic effect of each medicine and relief from adverse effects. Amyloid-b peptide (Ab), which is now recognized as central to the development of Alzheimer's disease (AD), is derived from the sequential proteolysis of amyloid precursor protein (APP) by band g-secretases. Secretase inhibitors are one of most attractive targets for therapeutic intervention in AD. However, because band g-secretases cleave not only APP but also other substrate proteins, strong inhibition of these secretases leads to severe adverse effects. Some nonsteroidal antiinflammatory drugs (NSAIDs) and cholesterol-lowering drugs (statins) can modify the production of Ab. Here, we report that a cocktail treatment with four drugs (NSAID, statin, and band g-secretase inhibitors) had additive effects on the reduction of Ab levels in cultured cells without competing with each other. Moreover, the fourdrug cocktail treatment caused no changes in processing of the g-secretase substrate Notch. This is suggests that this cocktail treatment could be a new therapeutic approach for AD. V

📜 SIMILAR VOLUMES

Amyloid β-peptide interactions with neur
Amyloid β-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease
✍ Yann Verdier; Márta Zarándi; Dr Botond Penke 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB

## Abstract The extracellular accumulation of amyloid‐beta (Aβ) in neuritic plaques is one of the characteristic hallmarks of Alzheimer's disease (AD), a progressive dementing neurodegenerative disorder of the elderly. By virtue of its structure, Aβ is able to bind to a variety of biomolecules, inc

Cytoplasmic domain of the β-amyloid prot
Cytoplasmic domain of the β-amyloid protein precursor of Alzheimer's disease: Function, regulation of proteolysis, and implications for drug development
✍ Megan L. Kerr; David H. Small 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB 👁 1 views

The ␤-amyloid protein precursor (APP) has been extensively studied for its role in amyloid production and the pathogenesis of Alzheimer's disease (AD). However, little is known about the normal function of APP and its biological interactions. In this Mini-Review, the role of the cytoplasmic domain o